Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.73B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.73M
Average 1.84M
Balance Sheet
Inspect the capital base behind the business.
Assets
$957.57M
FY 2026 · Annual
+23.4% YoYLiabilities
$104.97M
FY 2026 · Annual
+52.6% YoYEquity
$852.59M
FY 2026 · Annual
+20.5% YoYBalance Sheet
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 493.82M | 376.53M | 635.37M | 713.97M | 902.11M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 12.86M | 885K | 5.5M | 2.51M | 3.95M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 24.9M | 51.18M | 42.76M |
| Total Current Assets | 512.93M | 404.33M | 665.77M | 767.66M | 948.82M |
| Property, Plant & Equipment (Net) | 2.63M | 1.51M | 595K | 942K | 515K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 347K | 0 | 553K |
| Other Non-current Assets | 0 | 0 | 0 | 7.62M | 7.68M |
| Total Non-current Assets | 2.63M | 1.51M | 942K | 8.56M | 8.75M |
| Total Assets | 515.56M | 405.84M | 666.71M | 776.22M | 957.57M |
| Account Payables | 18.63M | 1.35M | 7.16M | 17.66M | 7.54M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 171K | 350K | 14.74M | 15.62M | 16.77M |
| Total Current Liabilities | 44.52M | 43.3M | 48.61M | 68.78M | 104.42M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 347K | 0 | 553K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 1.22M | 47K | 347K | 0 | 553K |
| Total Liabilities | 45.74M | 43.34M | 48.96M | 68.78M | 104.98M |
| Common Stock | 12K | 13K | 14K | 16K | 20K |
| Retained Earnings | (355.39M) | (566.35M) | (825.68M) | (1.24B) | (1.75B) |
| Accumulated OCI | 404K | 852K | 1.91M | 1.46M | 730K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 469.83M | 362.49M | 617.76M | 707.45M | 852.59M |
| Total Debt | 2.36M | 1.22M | 138K | 98K | 72K |
| Net Debt | (491.45M) | (375.31M) | (635.23M) | (713.87M) | (902.04M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $722.3M |
| Receivables | $138.0K |
| Other Current | $37.6M |
| Total Current Assets | $760.0M |
| PP&E (Net) | $262.0K |
| Other Non-current | $659.0K |
| Total Non-current Assets | $921.0K |
| Total Assets | $761.0M |
Analysis
Selected assets total $761.0M for Latest. The largest visible component is Cash & Equivalents at $722.3M, about 94.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| S-3ASR | S-3ASR filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 |
How much cash does IMVT have?
Immunovant, Inc. (IMVT) reported $902.11M in cash and equivalents in fiscal 2026.
How much debt does IMVT carry?
Immunovant, Inc. (IMVT) reported $72,000.00 of total debt, with net debt of -$902.04M.
Continue the stock analysis
Jump to another research area for this company.